The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice
Johnson RM et al
Saffati G, Kassab J, Orozco Rendon D, Hinojosa-Gonzalez DE, Kronstedt S, Lipshultz LI, Khera M
Disclosures: Kali Zhou: Gilead Sciences Inc: Grant/Research Support, Christopher Wong: Nothing to Disclose, Aaron Ahearn: Nothing to Disclose, Jeffrey Kahn: Orphalon: Single Advisory Board meeting 11/2023, Malinckrodt: Attended speaker's training session, never spoke, Orphalon: Single advisory board meeting, 2023, Norah Terrault: Elseiver: Royalties or patent beneficiary, GSK: Grant/Research Support, Eiger Pharmaceuticals: Grant/Research Support, Helio Health: Grant/Research Support, Durect Corp: Grant/Research Support, ImmunoCore: Grant/Research Support, HBV Foundation: Board member, AASLD: Executive role 1207 ASSESSING THE PREVALENCE OF CARDIOMETABOLIC RISK FACTORS IN PATIENTS REFERRED TO A STEATOTIC LIVER DISEASE CLINIC Yousef Almahanna 1 Ahmed Almohsen 1 Yi Nong Song 1 Amani Bajunayd 1 Jeemin Kim 1 Adrienne Abaya 1 Rokhsana Mortuza 1 Mohammad Qasim Khan 1 Juan Pablo Arab 1 , 1 University of Western Ontario Background: The metabolic syndrome is a known risk factor for development of hepatic steatosis
Stockwell BR, Jiang X (2020) The chemistry and biology of ferroptosis
